Open AccessPrognostic role of expression of angiogenesis markers in hepatocellular carcinoma: A bioinformatics analysis
Author(s) -
Yandong Miao,
Xiaolong Tang,
Jiangtao Wang,
Denghai Mi
Publication year - 2022
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v28.i30.4221
Subject(s) - vascular endothelial growth factor a , cancer research , angiogenesis , vascular endothelial growth factor , vascular endothelial growth factor c , receptor tyrosine kinase , hepatocellular carcinoma , placental growth factor , lymphangiogenesis , biology , downregulation and upregulation , angiopoietin , signal transduction , angiopoietin receptor , medicine , microbiology and biotechnology , cancer , vegf receptors , genetics , gene , metastasis
The expression of angiopoietin (ANGPT) 1, ANGPT2, vascular endothelial growth factor (VEGF) A, VEGFB, VEGFC, VEGFD, and placental growth factor (PGF) is significantly higher in tumor tissues than in normal tissues in both unpaired and paired hepatocellular carcinoma (HCC) samples. ANGPT2, VEGFB, VEGFC, and PGF are primarily involved in regulating the activation of the epithelial-mesenchymal transition pathway; ANGPT1 is primarily involved in regulating the activation of the RAS/mitogen-activated protein kinase and receptor tyrosine kinase (RTK) pathways; VEGFA is engaged in regulating the RTK activation pathway; and VEGFD is mainly involved in regulating the activation of the tuberous sclerosis protein/mammalian target of rapamycin pathway. There is a significant difference in overall survival between HCC patients with high and low expression of ANGPT2, PGF, VEGFA, and VEGFD. Disease free survival (DFS) is significantly shorter in HCC patients with high ANGPT2, PGF, and VEGFA expression than in those with low ANGPT2, PGF, and VEGFA expression.